XEBRA Study: An Observational Study of Xeloda (Capecitabine) in Combination With Docetaxel in First Line in Participants With HER2-Negative Metastatic Breast Cancer

Hoffmann-La Roche46 enrolled

Overview

This multicenter observational study will evaluate the efficacy and safety of Xeloda (capecitabine) in combination with docetaxel in first-line therapy in participants with HER2-negative metastatic breast cancer. Participants will be followed for approximately 6 months of treatment.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Breast Cancer

Interventions

capecitabineDRUG

Participants received capecitabine according to individualized physician-prescribed regimen.

docetaxelDRUG

Participants received docetaxel according to individualized physician-prescribed regimens.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult participants, \>/= 18 years of age * HER2-negative metastatic breast cancer * Participants initiated on first-line therapy with Xeloda and docetaxel in accordance with the Summary of Product Characteristics; participants who started treatment with Xeloda and docetaxel no more than 3 months before enrollment in this study are also eligible Exclusion Criteria: * Contraindications to Xeloda treatment according to the Summary of Product Characteristics

Locations (14)

Unnamed facility

Budapest, Hungary

Unnamed facility

Budapest, Hungary

Unnamed facility

Budapest, Hungary

Unnamed facility

Budapest, Hungary

Outcomes

Primary Outcomes

Progression-free Survival (PFS)

The time from enrollment until disease progression, assessed as the time to tumor progression, as evaluated by regular examinations per routine clinical practice, or death from any cause.